Medicity is a research laboratory at the Medical Faculty of the University of Turku.
We provide the laboratory, infrastructure, and office space for altogether about 100 scientists and technicians. Our basic goal is to provide our researchers with stimulating research and training environment and produce high-quality research in biomedicine and translational medicine. We are highly international as about one-fourth of our scientists come from abroad.
One of Medicity’s central expertise is in imaging including cell, tissue, and live animal imaging. As examples of this, Medicity has been a key player in setting up an ultramodern multiphoton microscope, small animal PET, and IVIS imaging systems. In addition, Medicity extensively contributes to Turku Bioimaging and to the animal facility infrastructure. The areas of research span from the basic research up to clinically-oriented projects. The work performed in Medicity is recognized both nationally and internationally as Medicity houses a group belonging to the Center of Excellence in Translational Cancer Biology and two of the Professors have received Anders Jahre Senior Prizes (the biggest medical prize in Scandinavia).
Kari Kurppa received 100 000€ funding from Instrumentarium Science Foundation for research project on "Preventing minimal residual disease following targeted cancer therapy". [Mar. 17 Instrumentarium Science Foundation]
Mari-Liis Mikk from Jorma Ilonen's Immonology group received a Grant for Completing a Doctoral Degree 2019 from Faculty of Medicine and Doctoral Programme at University of Turku. (September 25)
Dissertation of Norma Jäppinen on the topic ”PLVAP as the Gatekeeper of Endothelial Cell Permeability and Leukocyte Migration” Friday October 11th at 12PM (Turun yliopisto, PharmaCity, Pha1-auditorium, Itäinen Pitkäkatu 4, Turku)
Kristiina Santalahti from Jalkanen Lab received an Award for the Best Doctoral Thesis from Finnish Society for Immunology. (August 21)
Reetta Virtakoivu (Hollmen Lab) received a postdoc grant from Emil Aaltosen Säätiö. (Emil Aaltosen Säätiö 8.5)
Antibody Therapy That Trains Phagocytes to Destroy Tumors Is Tested in Patients (Drug Discovery Feb 22nd)
Antibody Therapy Training Phagocytes to Destroy Tumours Now Tested on Patients (University of Turku 20.2)
Training Phagocytes to Destroy Tumors (Nordic Life Science News Feb 20th)
Uudenlaisesta vasta-ainehoidosta lupaavia tuloksia (Syöpäsäätiö 20.2)
Here you can find selected publications from groups who work/worked at Medicity
- Early childhood CMV infection may decelerate the progression to clinical type 1 diabetes. Ekman I, Vuorinen T, Knip M, Veijola R, Toppari J, Hyöty H, Kinnunen T, Ilonen J, Lempainen J. Pediatr Diabetes. 2019 Feb;20(1):73-77. doi: 10.1111/pedi.12788. Epub 2018 Nov 19.
- Francisco R. López-Picón, Corresponding address, Anna K. Kirjavainen, Sarita Forsback, Jatta S. Takkinen, Dan Peters, Merja Haaparanta-Solin, Olof Solin. In vivo characterization of a novel norepinephrine transporter PET tracer [18F]NS12137 in adult and immature Sprague-Dawley rats. Theranostics 2019; 9(1):11-19. doi:10.7150/thno.29740.
- Laurikainen H, Tuominen L, Tikka M, Merisaari H, Armio RL, Sormunen E, Borgan F, Veronese M, Howes O, Haaparanta-Solin M, Solin O, Hietala J; METSY group. Sex difference in brain CB1 receptor availability in man.Neuroimage. 2019 Jan 1;184:834-842. doi: 10.1016/j.neuroimage.2018.10.013.
- Krzyczmonik A, Keller T, López-Picón FR, Forsback S, Kirjavainen AK, Takkinen JS, Wasilewska A, Scheinin M, Haaparanta-Solin M, Sączewski F, Solin O. Radiosynthesis and Preclinical Evaluation of an α2A-Adrenoceptor Tracer Candidate, 6-[18F]Fluoro-marsanidine. Mol Imaging Biol. 2019 Feb 1. doi: 10.1007/s11307-019-01317-6.
- Zeiner J, Loukovaara S, Losenkova K, Zuccarini M, Korhonen AM, Lehti K, Kauppinen A, Kaarniranta K, Müller CE, Jalkanen S, Yegutkin GG. Soluble and membrane-bound adenylate kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage. J Mol Med (Berl). 2019 Mar;97(3):341-354. doi: 10.1007/s00109-018-01734-0.
- Tadayon S, Dunkel J, Takeda A, Halle O, Karikoski M, Gerke H, Rantakari P, Virtakoivu R, Pabst O, Salmi M, Hollmén M, Jalkanen S. Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science Immunology. 2019 Mar 29;4(33). doi: 10.1126/sciimmunol.aat0297.
- Krzyczmonik A, Keller T, López-Picón FR, Forsback S, Kirjavainen AK, Takkinen JS, Wasilewska A, Scheinin M, Haaparanta-Solin M, Sączewski F, Solin O. Radiosynthesis and Preclinical Evaluation of an α2A-Adrenoceptor Tracer Candidate, 6-[18F]Fluoro-marsanidine. Molecular Imaging and Biology . 2019 Feb 1. doi: 10.1007/s11307-019-01317-6.
- Viisanen T, Gazali AM, Ihantola EL, Ekman I, Näntö-Salonen K, Veijola R, Toppari J, Knip M, Ilonen J, Kinnunen T. FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children. Frontiers in Immunology. 2019 Jan 22;10:19. doi: 10.3389/fimmu.2019.00019. eCollection 2019.
Petar Petrov, Alexey V. Sarapulov, Lel Eöry, Cristina Scielzo, Lydia Scarfò, Jacqueline Smith, David W. Burt & Pieta K. Mattila. Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control.Scientific Reports. 2019; 9: 4155.
S. K. Vainio, A. M. Dickens, J. Tuisku, O. Eskola, O. Solin, E. Löyttyniemi, D. C. Anthony, J. O. Rinne, L. Airas and M. Haaparanta-Solin. Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation. EJNMMI Research. 2019 Apr 9:38
Junker A, Renn C, Dobelmann C, Namasivayam V, Jain S, Losenkova K, Irjala H, Duca S, Balasubramanian R, Chakraborty S, Börgel F, Zimmermann H, Yegutkin GG, Müller CE, Jacobson KA. Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. Journal of Medicinal Chemistry. 2019 Apr 11;62(7):3677-3695.
Snellman A, Takkinen JS, López-Picón FR, Eskola O, Solin O, Rinne JO, Haaparanta-Solin M. Effect of genotype and age on cerebral [18F]FDG uptake varies between transgenic APPSwe-PS1dE9 and Tg2576 mouse models of Alzheimer's disease. Scientific Reports. 2019 Apr 5;9(1):5700.
Marjaana Mäkinen Eliisa Löyttyniemi Maarit Koskinen Mari Vähä-Mäkilä Heli Siljander Mirja Nurmio Juha Mykkänen Suvi M Virtanen Olli Simell Heikki Hyöty Jorma Ilonen Mikael Knip Riitta Veijola Jorma Toppari. Serum 25-Hydroxyvitamin D Concentrations at Birth in Children Screened for HLA-DQB1 Conferred Risk for Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism, Volume 104, Issue 6, June 2019, Pages 2277–2285.
Jalkanen S, Salmi M. Lymphatic endothelial cells of the lymph node. Nature Reviews Immunology. 2020 Feb 24.
Losenkova K, Paul M, Irjala H, Jalkanen S, Yegutkin GG. Histochemical Approach for Simultaneous Detection of Ectonucleotidase and Alkaline Phosphatase Activities in Tissues. Methods in Molecular Biology. 2020;2041:107-116.
Motiani KK, Savolainen AM, Toivanen J, Eskelinen JJ, Yli-Karjanmaa M, Virtanen KA, Saunavaara V, Heiskanen MA, Parkkola R, Haaparanta-Solin M, Solin O, Savisto N, Löyttyniemi E, Knuuti J, Nuutila P, Kalliokoski KK, Hannukainen JC. Effects of short-term sprint interval and moderate-intensity continuous training on liver fat content, lipoprotein profile, and substrate uptake: a randomized trial. Journal of Applied Physiology (1985). 2019 Jun 1;126(6):1756-1768.
Sanjay Bhattarai, Jan Pippel, Anne Meyer, Marianne Freundlieb, Constanze Schmies, Aliaa Abdelrahman, Amelie Fiene, Sang‐Yong Lee, Herbert Zimmermann, Ali El‐Tayeb, Gennady G. Yegutkin, Norbert Sträter, Christa E. Müller. X‐Ray Co‐Crystal Structure Guides the Way to Subnanomolar Competitive Ecto‐5′‐Nucleotidase (CD73) Inhibitors for Cancer Immunotherapy. Advanced Therapeutics. 2019; Jul 31.
Takeda A, Hollmén M, Dermadi D, Pan J, Brulois KF, Kaukonen R, Lönnberg T, Boström P, Koskivuo I, Irjala H, Miyasaka M, Salmi M, Butcher EC, Jalkanen S. Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils. Immunity. 2019 Aug 1. pii: S1074-7613(19)30297-3.
Laura Kähäri, Ruth Fair-Mäkelä, Kaisa Auvinen, Pia Rantakari, Sirpa Jalkanen, Johanna Ivaska, Marko Salmi. Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes. Journal of Clinical Investigation. 2019 Jun 24;130:3086-3102.
University of Turku, Medicity
Biocity, Tykistökatu 6A 4th floor
Professor of Medical Biochemistry,
Faculty of Medicine, University of Turku
MediCity Research Laboratories and Turku Center for Biotechnology
University of Turku and Åbo Akademi University
Cancer Research Laboratories, FICAN West
klaus.elenius [at] utu.fi
Description of Research
Our goal is to understand how receptor tyrosine kinases (RTK) regulate the pathogenesis of human diseases, such as cancer. This information is needed for the development of molecularly targeted therapies. To recognize aberrations of RTK signaling in diseased tissue our laboratory also works on the molecular mechanism by which RTKs control normal processes, such as embryonic development. The work mainly focuses on the ErbB family of RTKs. Our laboratory has contributed to the field by e.g. by characterizing novel RTK signaling mechanisms, by identifying novel ErbB4 isoforms, and by determining the role of ErbBs and their ligands in angiogenesis.
• Screens for predictive RTK mutations
• Novel RTK signaling mechanisms
• Development of preclinical models for development novel RTK inhibitors
• Sequencing of RTK inhibitor drug administration with cytotoxic agents
• In vitro “basket trials” with ErbB inhibitor drugs
• RTK signaling in angiogenesis and cardiovascular diseases
• RTKs in pediatric malignancies
• Biological role of novel ErbB4 isoforms in diseases and development
Scientific Director, BioCity Turku (BioCity Turku)
Professor, Biochemistry (Department of Biochemistry)
jyrki.heino [at] utu.fi
Description of Research
Our research group is studying the structure¬–function relationship of the collagen receptor integrins. The most important methods used include the production of recombinant protein domains, functional assays and mutations of the domains, bioinformatics as well as the expression and analysis of the full-length receptor proteins on cell surface. This has lead to a project aimed at development of small molecular inhibitors for collagen receptors.
In addition to the structural work we are also interested in integrin signaling, especially atypical signaling mechanisms, including low avidity integrin–ligand interaction and signaling by nonactivated integrins. Most recently, we have studied the role of collagen receptor signaling in prostate cancer and the consequences of post-translational modifications, such as citrullination, of the integrin ligands in inflammation In these experiments we use the general methods of molecular cell biology, imaging by confocal microscopy and proteomics. In a separate project we have developed new software for quantitative bioimaging (BioImageXD).
Jarmo Käpylä, Senior Scientist, Ph.D., Docent
Pekka Rappu, Postdoctoral Researcher
Johanna Jokinen, Postdoctoral Researcher
Elina Siljamäki, Postdoctoral Researcher
Anna-Brita Puranen, Doctoral Candidates
Marjaana Ojalill, Doctoral Candidates
Salli Keinänen, Doctoral Candidates
Maria Tuominen, Laboratory Technician
Noora Virtanen, Undergraduate Student
Ville Jokinen, Undergraduate Student
Academy Research Fellow, Department of Clinical Medicine (Department of Clinical Medicine),
Adjunct Professor, MediCity Research Laboratory (Faculty of Medicine)
maijal [at] utu.fi
Description of Research
Our research exploits a unique scavenger receptor Clever-1, expressed on a subpopulation of immunosuppressive macrophages, to alleviate tumor related inflammation and develop Clever-1 as a companion therapeutic, diagnostic, and prognostic biomarker to treat and identify patients under immunosuppression. This involves the use of in vivo tumor models and sophisticated immunological assays with cutting-edge technology and state-of-the-art imaging combined with fresh human cancer patient material to elucidate the function of Clever-1 in controlling macrophage mediated local and systemic immune responses. Our results potentially have a high impact in understanding the mechanism of macrophage-mediated immunosuppression in cancer and promoting anti-Clever-1 immunotherapy into clinical trials where it may have benefits in comparison with currently available immune activating drugs.
Professor, Institute of Biomedicine (Institute of Biomedicine),
Diagnostics and Bioimaging
pekka.e.hanninen [at] utu.fi
Description of Research
Laboratory of Biophysics develops instrumentation and methods for light microscopy, correlative multimodal microscopy and bio-analysis in general. The key application areas lie broadly within life-sciences research from basic research to applications but also in industrial processes of food technologies and industrial process waters are today on the agenda.
The group has recently developed new super-resolution techniques for 3D super-resolved tomography including software, super-resolution compatible nano-probes, super-resolution compatible in-vitro model for studies in bone-biology and most recently photoacoustic microscopy methods (PAM). In 2014 one of the former group members, Stefan Hell, was awarded the Nobel Prize in Chemistry for his work in the development of super-reselving microscopes, work that originated from our laboratory in the mid 90’s.
On the bioanalysis side, the group has developed a new type of chemical fingerprinting technique that has been applied from diagnostics of oral cancer to profiling of microbiota in the gut and analysis of bacteria in urine. The same technology has been demonstrated in several applications in the food industry and the technology has found its way also to production in the assessment of industrial process waters.
The group has been able to produce results that have lead both academic merits and into industrially exploited applications by a) licensing of the developed technologies to e.g. Leica Microsystems (2-photon microscopy, STED microscopy) and b) through own startups (Arcdia International Oy and Aqsens Oy)
Elnaz Fazelli, Doctoral Candidate (shared with groups of prof. J. Peltonen and prof. J. Eriksson/ÅA)
Elena Tcarenkova, Doctoral Candidate
Professor, Institute of Biomedicine (Institute of Biomedicine)
jsilonen [at] utu.fi
Department of Pediatrics, Institute of Clinical Medicine,
University of TurkuUnit for Rare Diseases,
Turku University Hospital
nojoaa [at] utu.fi
Description of Research
These diseases result from interaction between genetic and environmental factors. The single most important gene region regulating immune response is the (MHC) major histocompatibility complex, in humans the HLA gene complex. Polymorphisms within genes in this region are largely responsible for the genetic susceptibility to many autoimmune diseases including type 1 diabetes, celiac disease, ankylosing spondylitis, rheumatoid arthritis and multiple sclerosis.
We have performed genetic studies in the series of the Finnish Pediatric Diabetes Register and genetic screening for disease susceptibility for recruitment of subjects to several type 1 diabetes associated follow-up projects including DIPP, TRIGR, PRODIA, FINDIA, DIABIMMUNE and TEDDY where children at genetic risk have been followed-up in attempt to identify environmental risk factors and understand pathogenetic mechanisms responsible for destruction of pancreatic ß-cells.
Results based on definition of both HLA and non-HLA gene polymorphisms as well as clinical characteristics suggest heterogeneity in pathogenetic mechanisms of type 1 diabetes and different interactions between genetic and environmental factors in various phases of the autoimmune process leading to clinical disease.
Many of the mentioned studies have included trials attempting to prevent clinical type 1 diabetes either before the appearance of diabetes associated autoimmunity (primary prevention) or after appearance of diabetes associated autoantibodies (secondary prevention).
Johanna Lempainen, Senior Researcher
Antti-Pekka Laine, Senior Researcher,
Minna Kiviniemi, Senior Researcher
Mari-Liis Mikk, Doctoral Candidate
Mia Karlsson, Laboratory Technician
Terhi Laakso, Laboratory Technician
Piia Nurmi, Laboratory Technician
Anne Suominen, Laboratory Technician
Ritva Suominen, Laboratory Technician
Institute of Biomedicine
sirpa.jalkanen [at] utu.fi
Description of Research
The overall goal of our research is to elucidate the mechanisms regulating the traffic of leukocytes and cancer cells in the body. Harmful leukocyte migration into the joints in rheumatoid arthritis and into the pancreas in diabetes are examples of diseases where leukocytes cause extensive destruction. These inflammatory diseases can be cured by inhibiting leukocyte trafficking. Also, metastasising malignant cells often use the same mechanisms as leukocytes when extravasating from blood to different organs or migrating via the lymphatics into distant sites. The results obtained can be utilized when new types of drugs are developed to treat harmful inflammations and cancer.
Senior Research Fellow, Laboratory of Organic Chemistry and Chemical Biology (Department of Chemistry)
jianwei.li [at] utu.fi
Description of Research
Molecular Systems Engineering is an emerging field by understanding the fundementals of molecular properties and dynamics in synthetic complex systems, and exploring sophisticated functions for advanced applications in biomedicine, materials and energy. Our laboratory uses the tools of dynamic combinatorial chemistry (DCC), supramolecular chemistry and computer chemistry to fabricate the framework of complex chemical systems, investigates the self-assembly in such systems and uncovers the working principles at molecular level behind them. We have learned that self-assembly can not only direct the formation of beautiful and intriguing structures i.e. catenanes and “Russian-doll”-like supramolecular architectures, but also promote the molecules to make copies of themselves as the living matters in nature. Currently we are trying to extend the board of DCC into the fields of materials science, enzymology and biology by three lines of research: 1) dynamic combinatorial biomaterials for controlling cell behaviors; 2) enzyme-directed DCC; and 3) DCC in vivo.
Academy Research Fellow, Institute of Biomedicine
pieta.mattila [at] utu.fi
Description of Research
Our research group studies the regulation of lymphocyte activation with a special focus on the control provided by the cellular cytoskeleton. We integrate immunological and cell biological methods including advanced light microscopy, biochemistry, and cellular and in vivo models, to gain novel understanding on the function and regulation of the immune system.
Merja Haaparanta-Solin Adjunct Professor,
Senior Researcher, Head of Preclinical Imaging,
Turku PET Centre
merja.haaparanta-solin [at] utu.fi
Tove Grönroos, Adjunct Professor,
Senior Researcher, Manager of Preclinical Metabolic Research,
Turku PET Centre
tovgro [at] utu.fi
Fracisco López-Picón, Senior Researcher and Manager of Preclinical Neuroscience Imaging
francisco.lopez [at] utu.fi
Description of Research
The general goals of the Preclinical and translational research unit are a) to evaluate and develop new PET tracers, b) to be a bridge between basic and clinical research in all areas where the PET Centre is involved, c) to be a reference core facility for basic biomedical research, d) to collaborate with pharmaceutical companies in drug development, and e) to be an important training centre for techniques related to animal imaging.
The preclinical unit actively participates in the novel radiotracer development at the Turku PET Centre including tissue penetration, target validation and metabolite analysis in experimental animals, and metabolism in the first in man studies. We collaborate extensively with the Central Animal Laboratory (CAL), the Turku Centre for disease Models (TCDM), and Auria Biobank for our research with animal models and tissues.
The preclinical unit works in numerous research projects. Among these projects are specific preclinical and basic science projects, internal collaborations with the Radiopharmaceutical chemistry unit and clinicians from different units. In addition, we have many collaboration projects with local, national, and international academic and commercial partners.
Cardiac and metabolic research
Most preclinical (nonclinical) work is done using small animals (mice, rats) whose physiology is dissimilar to human and, therefore, also the translation of imaging is challenging. The aim is to develop and validate pig models for coronary heart disease and heart failure. This work is done jointly with teams in Osaka, Canada and Kuopio. These models enable the investigation of disease mechanisms at the cellular level parallel with testing and the validation of new tracers and imaging methods.
The oncology group aims to improve diagnostic imaging by developing new PET tracers, evaluating their usage in different experimental settings and to translate and introduce research findings into the clinic. The research focuses on imaging the tumour microenvironment by targeting specific proteins and genes, or general processes that occurs in tumours and are important in treatment planning and therapy resistance. Proliferation, apoptosis, angiogenesis, oxygen metabolism, inflammatory response and oncogene expression is of central importance in development of novel biologically targeted agents and adaptive radiotherapy.
The preclinical research in neuroscience will continue the current work in neurodegeneration, and neuroinflammation, and will expand into new research in neuropsychiatry in collaboration with radiochemistry and clinicians. The focus will mainly be on the following topics:
1) Development of novel radiotracers for neuroscience will focus on the detection of tau tangles, neuroinflammation, norepinephrine transporter and synaptic function.
2) Identification of novel mechanism of disease in neurodegeneration, neuroinflammation and psychiatric diseases, and in the identification of novel targets for tracer development and drug targeting.
Marko Salmi, MD, PhD
Professor of Molecular Medicine,
Medicity Research Laboratory
masalmi [at] utu.fi
Description of Research
Leukocyte migration from the blood into tissues is critical for generation of normal immune responses. Abnormal leukocyte traffic contributes to the pathogenesis of all inflammatory diseases and several other diseases, such as cancer. We study the molecules on blood and lymphatic vessels and their counter-receptors on leukocytes, which mediate the different steps of leukocyte migration in the body. We have identified several new adhesion molecules (e.g. vascular adhesion protein-1 (VAP-1), CD73, stabilin-1, plasmalemma vesicle associated protein (Plvap)) mediating leukocyte migration, dissected the molecular mechanisms involved, and studied the therapeutic value of modulating the function of these and other adhesion receptors in inflammation and cancer. We also elucidate the differentiation of immune suppressive types of monocytes/macrophages in the body. Moreover, we analyze the value of adhesion molecules and cytokines as biomarkers of disease.
Members of the Research Group
Eichin, Dominik, Doctoral Candidate
Félix, Inês, Doctoral Candidate
Jäppinen, Norma, Doctoral Candidate
Kähäri, Laura, Doctoral Candidate
Lokka, Emmi, Doctoral Candidate
Mokkala, Elias, Doctoral Candidate
Väänänen, Etta-Liisa, Laboratory Technician
Professor, Pulmonary Diseases and Clinical Allergology (Department of Clinical Medicine)
johsav [at] utu.fi
Description of research
Research project titles
A Novel Glycocluster Molecule for treatment of Allergy and Cancer
Mechanisms of Specific Oral Tolerance Induction (SOTI) in Food Allergic Children
The primary objective of our interdisciplinary research is to develop new glycocluster molecules to be used in microbial, allergy and cancer vaccines. The secondary object is to explore the mechanisms of action of the glycoclusters. Immunostimulatory beta-1,2-linked mannoside cluster molecules are structurally optimized and derivatized, including new covalently linked bioconjugates and fluorine-labeled targets. Advanced NMRspectroscopic methods are applied for conformational and lectin-binding studies. Immunostimulatory properties are investigated in vitro and in vivo in murine models of allergic asthma, chronic allergic inflammation and melanoma tumors. As a result, fundamental understanding relevant to application of glycobiology to immunotherapy will be achieved.
Members of the research group
Leena Kavén-Honka, laboratory technician
Savolainen J, Ranta K, Mukherjee C, Leino R. Immunostimulatory Compounds and Uses Thereof, Finn. Pat. Appl. FI20115631 (to University of Turku and Åbo Akademi University); U.S. Pat Appl. 61/499,229 (Filed June 21, 2011); Int. Appl. PCT/FI/2012/050650 (Filed June 21, 2012); U.S. Pat. 9221861 (Issued Dec. 29,
Mukherjee C, Ranta K, Savolainen J, Leino R. Synthesis and Immunological Screening of ß-Linked Monoand Divalent Mannosides. Eur J Org Chem, 2012; 2957-2968.
Linnamaa P, Nieminen K, Koulu L, Tuomasjukka S, Kallio H, Yang B, Tahvonen R, Savolainen J. Proinflammatory and Th2 type cytokine responses in PBMC in infants are associated with parental smoking. Clin Exp Allergy, 2012;42:1472-1478.
Mukherjee C, Mäkinen K, Savolainen J, Leino R. Chemistry and biology of oligovalent β-(1,2)-linked oligomannosides: New insights into carbohydrate based adjuvants in immunotherapy. Chem-Eur J. 2013, 19:7961-74.
Rahkila J, Panchadhayee R, Ardá A, Jiménez-Barbero J, Savolainen J, Leino R. Acetylated Trivalent Mannobioses: Chemical Modification, Structural Elucidation, and Biological Evaluation. ChemMedChem. 2016;11:562-74.
Professor, Institute of Biomedicine
jortop [at] utu.fi
Description of Research
DIPP study has screened more than 200 000 newborns for genetic risk of T1D and about 17 000 children have participated in the follow-up that includes regular visits, interviews and collection of various kinds of biological samples until the age of 15 or diagnosis of T1D. The recruitment started in 1994 and is still continuing constituting a data and sample repository of dynamic birth cohort that includes a large number of children at different stages of the disease process.
DIPP study welcomes proposals for collaboration studies to facilitate the international research efforts aiming at identification of causes of T1D and developing prevention and better treatments for the disease. The collaboration studies can include various kinds of studies covering e.g. analyses of the clinical samples and/or the data collected in the DIPP study as well as clinical trials.
Satu Ruohonen, Medical Laboratory Technologist
Minna Romo, Medical Laboratory Technologist
Zhian Othmani, Medical Laboratory Technologist
Elina Mäntymäki, Medical Laboratory Technologist
Mari Vähä-Mäkilä, Senior Researcher
Marjaana Mäkinen, Doctoral Student
Senior Research Fellow, Joint Biotechnology Laboratory (JBL)
anton.zavialov [at] utu.fi
Description of Research
We work in the field of structural biology and structure-based drug design. Our main methods are x-ray crystallography and cryo-electron microscopy. The main focus of our research is the unraveling of molecular mechanisms governing the interplay between microbial pathogens and their hosts, and the exploitation of these finding in medicine. We are particularly interested in host-pathogen interactions during the early steps of infection: bacterial attachment and biofilm formation mediated by fimbrial adhesins and host tissue invasion mediated by the Type III secretion system. Blocking these steps could prevent infections caused by antibiotic-resistant pathogens. Another line of our research explores the intricate cell signaling mechanism of the novel growth factor-enzyme, adenosine deaminase type 2 (ADA2). This study paves the way for the development of novel means to treat blood cancers and vascular disorders, including a genetic disease called deficiency of ADA2 (DADA2). In addition, we develop a novel ADA-based immuno-oncological therapy of advanced cancers.
Minna Tuittila, Postdoctoral Researcher
Sari Paavilainen, Senior Researcher
Henri Malmi, Doctoral Candidate
Maksym Skaldin, Doctoral Candidate
Vladimir Zav’yalov, Visiting Professor
Skaldin M, Tuittila M, Zavialov And. V & Zavialov Ant. V (2018) Secreted bacterial adenosine deaminase is an evolutionary precursor of adenosine deaminase growth factor. Molecular Biology and Evolution, 35:2851-2861.
Pakharukova N, McKenna S, Tuittila M, Paavilainen S, Parilova O., Malmi H, Matthews S. & Zavialov AV (2018) Archaic and alternative chaperones preserve pilin folding energy by providing incomplete structural information. Journal of Biological Chemistry, 293(44):17070-17080.
Pakharukova N, Tuittila M, Paavilainen S, Malmi H, Parilova O, Teneberg S, Knight S & Zavialov AV‡ (2018) Structural basis for Acinetobacter baumannii biofilm formation. Proc Natl Acad Sci U S A 115, 5558-5563
Gurung J, Amer A, Francis MK, Costa TRD, Chen S, Zavialov AV & Francis MS (2018) Heterologous Complementation Studies With the YscX and YscY Protein Families Reveals a Specificity for Yersinia pseudotuberculosis Type III Secretion. Frontiers in cellular and infection microbiology 8, 80.
Pakharukova N, Roy SP, Tuttila MT, Paavilanen S, Ingars A-K, Skaldin M, Lamminmäki U, Härt T, Teneberg S. & Zavialov AV (2016). Structural basis for Myf and Psa fimbriae-mediated tropism of pathogenic strains of Yersinia for host tissues. Molecular Microbiology, 102, 593–610.
Pakharukova N., Garnett G, Tuittila MT, Paavilainen S., Diallo M, Xu Y., Matthews S. and Zavialov AV (2015) Structural insight into archaic and alternative chaperone-usher pathways reveals non-classical mechanism of pilus biogenesis. PLoS Pathogens, 11:e1005269.
Amer A, Gurung J, Costa T, Zavialov AV, Forsberg Å & Francis M (2015) YopN and TyeA hydrophobic contacts required for regulating Ysc-Yop type III secretion activity by Yersinia pseudotuberculosis. Frontiers in cellular and infection microbiology, 6:66.
Berry A, Yang Y, Pakharukova N, Garnett J, Lee W, Cota E, Marchant J, Roy S, Tuittila M, Liu B, Inman K, Ruiz-Perez F, Mandomando I, Nataro J, Zavialov AV and Matthews S (2014) Structural insight into host recognition by aggregative adherence fimbriae of enteroaggregative Escherichia coli. PLoS Pathogens, 10, e1004404